Triple reuptake inhibitors: A patent review (2006-2012)

Expert Opinion on Therapeutic Patents

Volumn 24, Issue 2, 2014, Pages 131-154

  Shao, Liming ^a   Li, Wei ^a   Xie, Qiong ^a   Yin, Hong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Attention deficit hyperactivity disorder; Depression; Dopamine; Monoamine transporters; Neuropathic pain; Neurotransmitter; Norepinephrine; Serotonin; Structure activity relationships; Triple reuptake inhibitors

Indexed keywords

TRIPLE REUPTAKE INHIBITOR;

ANTIDEPRESSANT ACTIVITY; ATTENTION DEFICIT DISORDER; BINDING AFFINITY; BINDING ASSAY; BIOLOGICAL ACTIVITY; CHEMICAL STRUCTURE; COMPARATIVE STUDY; DEPRESSION; DRUG DEPENDENCE; DRUG INDUSTRY; EATING DISORDER; FORCED SWIM TEST; HALF LIFE TIME; HUMAN; INFLAMMATION; LOCOMOTION; MENTAL DISEASE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NERVE CELL PLASTICITY; NORADRENALIN UPTAKE; PAIN; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RACEMIC MIXTURE; REVIEW; SEROTONIN UPTAKE; STEREOISOMERISM; TAIL SUSPENSION TEST; TOPICAL ANESTHESIA;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANTIDEPRESSIVE AGENTS; DOPAMINE UPTAKE INHIBITORS; DRUG AND NARCOTIC CONTROL; DRUG DESIGN; HUMANS; MOLECULAR STRUCTURE; NEUROTRANSMITTER UPTAKE INHIBITORS; PATENTS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84892742810     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2014.859676     Document Type: Review

References (143)

1. Elias LJ, Saucier DM. Neuropsychology: clinical and experimental foundations. Pearson; Boston: 2005
2. Schultz W. Multiple dopamine functions at different time course. Annu Rev Neurosci 2007;30:259-88
3. Iversen L. Neurotransmitter transporters: fruitful targets for CNS drug discovery. Mol Psychiatry 2000;5:357-62
4. Torres GE, Gainetdinov RR, Caron MG. Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci 2003;4: 13-25
5. Barlow DH, Durand VM. Abnormal psychology: an integrative approach. 5th edition. Wadsworth Cengage Learning; Belmont, CA: 2009
6. Preskorn SH, Ross R, Stanga CY. Antidepressants: past, present and future. Springer; Berlin: 2004
7. Wong DT, Horng JS, Bymaster FP, et al. A selective inhibitor of serotonin uptake: lilly 110140, 3-(p-Trifluoromethylphenoxy)-n-methyl-3- phenylpropylamine. Life Sci 1974; 15:471-9
8. Redrobe JP, Bourin M, Colombel MC, et al. Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity. Psychopharmacology (Berl) 1998; 138:1-8
9. Paul IA. Pharmaceutical news. 2001;8:33
10. Castrén E. Is mood chemistry? Nat Rev Neurosci 2005;6:241-6
11. Shelton RC, Tomarken AJ. Can recovery from depression be achieved? Psychiatr Serv 2001;52:1469-78
12. McCabe C, Mishor Z, Cowen PJ, et al. Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment. Bio Psych 2010;67:439-45
13. El Mansari M, Guiard BP, Chernoloz O, et al. Relevance of norepinephrinedopamine interactions in the treatment of major depressive disorder. CNS Neurosci Ther 2010;16:e1-17
14. Miller HL, Delgado PL, Salomon RM, et al. Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch Genet Psychiatry 1996;53:117-28
15. Tremblay P, Blier P. Catecholaminergic strategies for the treatment of major depression. Curr Drug Targets 2006;7:149-58
16. Skolnick P, Popik P, Janowsky A, et al. Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor. Eur J Pharmacol 2003;461:99-104
17. Beer B, Stark J, Krieter P, et al. DOV 216,303, a "triple" reuptake inhibitor: safety, tolerability, and pharmacokinetic profile. J Clin Pharmacol 2004;44:1360
18. Skolnick P, Popik P, Janowsky A, et al. "Broad spectrum" antidepressants: (-)-1-(3,4-dichlorophenyl)-3-azabicyclo [3,1,0] hexane? Life Sci 2003;73:3175-9
19. Skolnick P, Basile AS. Triple reuptake inhibitors ("broad spectrum" antidepressants). CNS Neurol Disord Curr Drug Targets 2007;6:141-9
20. Millan MJ. Dual-and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs. Neurotherapeutics 2009;6:53-77
21. Perovic B, Jovanovic M, Miljkovic B, et al. Getting the balance right: established and emerging therapies for major depressive disorders. Neuropsychiatr Dis Treat 2010;6:343-64
22. Blier P, Ward HE, Tremblay P, et al. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 2010; 167:281-8
23. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STARD report. Am J Psychiatry 2006;163: 1905-17
24. Tran P, Skolnick P, Czobor P, et al. Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Psychiatr Res 2012;46:64-71
25. Nowak G, Arnt J, Hyttel J, et al. Down-regulation of dopamine D-2, 5-HT2 receptors and beta-adrenoceptors in rat brain after prolonged treatment with a new potential antidepressant, Lu 19-005. J Neural Transm 1985;64: 227-38
26. Arnt J, Christensen AV, Hyttel J. Pharmacology in vivo of the phenylindan derivative, Lu 19-005, a new potent inhibitor of dopamine, noradrenaline and 5-hydroxytryptamine uptake in rat brain. Naunyn Schmiedebergs Arch Pharmacol 1985;329:101-7
27. Res triangle inst. Cocaine receptor binding ligands. WO9309814; 1993
28. Neurosearch A/S. Process for the preparation of 2-(ethoxymethyl)-tropane derivatives. WO9730997; 1997
29. Glaxo Group Ltd. Hydrochloride salt and azabicyclo[3,2,1]octane derivative. WO10458; 2008
30. Boehringer ingelheim international GmbH. Solid pharmaceutical preparation form. WO049024; 2005
31. Neurosearch A/S. Monoamine neurotransmitter re-uptake inhibitor for neuroprotection. WO028769; 2007
32. Neurosearch A/S. Monoamine neurotransmitter re-uptake inhibitors for neuroprotection in patients suffering from an advanced stage of a mental disease. WO028770; 2007
33. Boehringer ingelheim international GmbH. Pharmaceutical composition for the treatment of disorders of sexual desire. WO006738; 2007
34. Neurosearch A/S. A method for treatingeating disorders. WO065845; 2009
35. Neurosearch A/S. A method for treating addiction. WO065846; 2009
36. Neurosearch AS. 8-Azabicyclo[3,2,1]oct-2-ene derivatives, their preparation and use. WO9713770; 1997
37. Neurosearch A/S. Novel enatiomers and their use as monoamine neurotransmitter re-uptake inhibitors. WO108789; 2006
38. Neurosearch A/S. Novel azabicyclo[3,2,1] oct-2-ene derivatives and their use as monoamine neurotransmitter-uptake inhibitors. WO025978; 2007
39. Neurosearch A.S. 8-azabicyclo[3,2,1]oct-2-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO057848; 2010
40. Boehringer ingelheim international GmbH. Method for producing (1R, 5S) anhydroecgonine ester salts. WO043793; 2009
41. Neurosearch A/S. (+)-and (-)-8-alkyl-3-(trifluoralkylsulfonyloxy)-8- azabicycl (3,2,1)oct-2-ene. WO108790; 2006
42. Neurosearch A/S. 3-aryloxy-8-azabicyclo[ 3,2,1]oct-6-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO131525; 2006
43. Neurosearch A/S. 8-aza-bicyclo[3,2,1] octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO054531; 2007
44. Neurosearch A/S. Novel phenylethynyl derivatives of 8-aza-bicyclo[3,2,1] octane and their use as monoamine neurotransmitter re-uptake inhibitors. WO098208; 2009
45. Neurosearch A/S. Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO093604; 2007
46. Neurosearch A/S. Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO074797; 2008
47. Neurosearch A/S. Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO074798; 2008
48. Neurosearch A/S. Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO130620;2010
49. Neurosearch A/S. Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO092061; 2011
50. Neurosearch A/S. Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO117289; 2011
51. Glaxo Group Ltd. Azabicyclo[3,2,1] octane derivatives. WO056520; 2009
52. Neurosearch A/S. Novel substituted diazabicyclo derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO106090; 2006
53. Neurosearch A/S. 3, 9-diazabicyclo[3,3,1] nonane derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention. WO090886; 2007
54. Neurosearch A/S. Novel 3, 8-diazabicyclo[ 3,2,1]octane-and 3,9-diazabicyclo[ 3,3,1]-noname-3-carboxylic acid ester derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO109517; 2009
55. Neurosearch A/S. 1-aza-bicyclo[3,3,1] noname or-3-ene derivatives and their use as monoamine neurotransmitter reuptake inhibitors. WO026208; 2010
56. N.V. Organon. 9-Azabicyclo[3,3,1] nonane derivatives as monoamine reuptake inhibitors. WO039563; 2007
57. Neuroscienze Pharmaness S.C.AR.L. Diazabicyclic compounds and microemulsions thereof. EP2149370; 2010
58. Shao L, Hewitt MC, Wang F, et al. Discovery of N-methyl-1-(1- phenylcyclohexyl) methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor. Bioorg Med Chem Lett 2011;21:123-34
59. Sepracor, Inc. Cycloalkylamines as monoamine reuptake inhibitors. WO081857; 2007
60. Sepracor, Inc. Triple reuptake inhibitors and methods of their use. WO075064; EP2370405,2010. US20110313013; 2011
61. Basile AS, Janowsky A, Golembiowska K, et al. Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain. J Pharmacol Exp Ther 2007;321: 1208-25
62. Skolnick P, Popik P, Janowsky A, et al. Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor. Eur J Pharmacol 2003;461:99-104
63. Skolnick P, Skolnick P, Popik P, et al. "Broad spectrum" antidepressants: is more better for the treatment of depression? Life Sci 2003;73:3175-9
64. Skolnick P, Krieter P, Tizzano J, et al. Antidepressant-like actions of DOV 216,303, a "triple" reuptake inhibitor. CNS Drug Rev 2006;123-34
65. Dov Pharmaceutical, Inc. (-)-1-(3,4-dichlorophenyl)-3-azabicyclo [3,1,0] hexane, compositions thereof, and uses for treating alcohol-related disorders. WO047837; 2007
66. Dov Pharmaceutical, Inc. Novel polymorphs of azabicyclohexane. WO023659; 2006
67. DOV Pharmaceutical, Inc. Methods and compositions for controlling body weight and appetite. WO/063673; 2008
68. DOV Pharmaceutical, Inc. Process for the synthesis of (+) and (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3,1,0] hexane. WO127396; 2007
69. DOV Pharmaceutical, Inc. Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3,1,0] hexanes. WO013856; 2008
70. McKinney AA. Preparation and use of (+)-1-(3, 4-dichlorophenyl)-3- azabicyclo [3, 1, 0] hexane in the treatment of conditions affected by monoamine neurotransmitters. US0258994; 2012
71. DOV Pharmaceutical, Inc. Novel 1-aryl-3-azabicyclo[3,1,0]hexanes: preparation and use to treat neuropsychiatric disorders. WO016155; 2007
72. DOV Pharmaceutical, Inc. Novel 1-heteroaryl-3-azabicyclo [3,1,0]hexanes, methods for their preparation and their use as medicaments. WO153937; 2008
73. GLAXO Group Ltd. Azabicyclic compounds as serotonine, dopamine and norepinephrine reuptake inhibitors. WO074716; 2008
74. GLAXO Group Ltd. Compounds. WO027293; 2009
75. GLAXO Group Ltd. 1,6-disubstituted 3-azabicyclo[3,1,0] hexane derivatives for use as triple reuptake inhibitors. WO141412; 2009
76. GLAXO Group Ltd. Chemical compounds. WO031771; 2008
77. Glaxosmithkline. Chemical compounds. US20080114049; 2008
78. GLAXO Group Ltd. Substituted azabicyclo[4,1,0]heptanes compounds for use as monoamine reuptake inhibitors. WO027294; 2009
79. GLAXO Group Ltd. 3-azabicyclo[4,1,0] heptanes derivatives useful as norepinephrine, serotonin or dopamine reuptake inhibitors. WO027295; 2009
80. GLAXO Group Ltd. Novel compounds. WO109608; 2009
81. GLAXO Group Ltd. Azabicyclo [4,1,0] heptane derivatives and their use as monoamine reuptake inhibitors. WO130672; 2010
82. GLAXO Group Ltd. Azabicyclo [4,1,0] heptane derivatives and their use as monoamine reuptake inhibitors. WO125033; 2010
83. GLAXO Group Ltd. Azabicyclo[4,10] heptane derivatives. WO133569; 2010
84. GLAXO Group Ltd. Tricyclic azabicyclo [4,1,0] heptane derivatives as inhibitors of serotonin, dopamine and norepinepherine re-uptake. WO46025; 2010
85. Ramot At Tel Aviv University Ltd. Novel serotonin reuptake inhibitors as drugs having peripheral-system-restricted activity. US20100260750; 2010
86. Kranzler. Prevention and treatment of functional somatic disorders, including stress-related disorders. US20090105222; 2009
87. SK Holding Co. Ltd. 3-substituted propanamine compounds. WO148290; 2009
88. SK Holding Co. Ltd. 3-or 4-substituted piperidine compounds. WO148291; 2009
89. Mayo foundation for medical education and research. Inhibiting neurotransmitter reuptake. WO089479; 2009
90. Mayo foundation for medical education and research. Inhibiting neurotransmitter reuptake. WO056773; 2011
91. Pfizer Products, Inc. Diphenyl ether monoamine reuptake inhibitor. WO036881; 2007
92. Sepracor, Inc. Pyrrolidine triple reuptake inhibitors. WO091268; 2010
93. Sunovion Pharmacueticals, Inc. Formulations, salts and polymorphs of transnorsertraline and uses thereof. WO069032; 2011
94. NIFE Therapeutics, S.L. Compounds and methods for selective diversity of olignucleotide molecules to specific neuron types. WO131693; 2011
95. Sepracor, Inc. Tetralone-based monoamine reuptake inhibitors. WO081542; 2007
96. F. Hoffmann-La Roche AG. Tetrahydroquinoline indole derivatives as monoamine reuptake inhibitors. WO067273; 2011
97. F. Hoffmann-La Roche AG. Pyrrolidinyl derivatives and uses thereof. WO115427; 2009
98. F. Hoffmann-La Roche AG. Aryl ketone as MRI. WO153178; 2009
99. Otsuka Pharmaceutical Co. Ltd. N, N-substituted 3-aminopyrolidine compounds useful as monoamines reuptake inhibitors. WO121218; 2006
100. Otsuka Pharmaceutical Co. Ltd. Medicinal material. JP2008137997; 2008
101. Takeda Pharmaceutical Co. Ltd. Pyrrolidine compound. WO123006; 2010
102. Takeda Pharmaceutical Co. Ltd. Heterocyclic compound. WO119528; 2009
103. Neurosearch A/S. Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO113297; 2004
104. Neurosearch A/S. Novel piperidine derivatives and their uses as monoamine neurotransmitter re-uptake inhibitors. WO025777; 2008
105. Neurosearch A/S. Novel N-phenylpiperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO131524; 2006
106. Neurosearch A/S. 1-phenethylpiperidine derivatives and their use as opioid receptor ligands. WO093603; 2007
107. Neurosearch A/S. N-aryl-N-piperidin-4-yl-propionamide derivatives and their use as opioid receptor ligands. WO077574; 2009
108. Neurosearch A/S. N-aryl-N-piperidin-4-yl-propionamide derivatives and their use as opioid receptor ligands. WO077584; 2009
109. Neurosearch A/S. N-aryl-N-piperiidin-4-yl-propionamide derivatives and their use as monoamine neurotransmitter reuptake inhibitors. WO077585; 2009
110. Neurosearch A/S. Novel piperidine-4-carboxylic acid phenyl-alkyl-amide derivatives and their use as monoamine neurotransmitter reuptake inhibitors. WO09173; 2009
111. Neurosearch A/S. Novel piperidine-4-acetamide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO023197; 2010
112. Neurosearch A/S. Novel piperidinebutyramide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO060852; 2010
113. Neurosearch A/S. Novel 4-benzhydriyltetrahydro-pyridine derivatives and their use as monoamine neurotransmitter reuptake inhibitors. WO109518; 2009
114. Neurosearch A/S. Novel 4-benzhydryloxy-tetraalkyl-piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO109519; 2009
115. Neurosearch A/S. Novel 3,9-diaza-spiro [5,5]undecane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO000463; 2007
116. Neurosearch A/S. Novel 3-aza-spiro[5,5] undec-8-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO000464; 2007
117. Neurosearch A/S. Novel 3-aza-spiro[5,5]-undecane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO000465; 2007
118. Feighner JP. Trazodone, a triazolopyridine derivative, in primary depressive disorder. J Clin Psychiatry 1980.41: 250-5
119. Auspex Pharmaceuticals, Inc. Substituted triazolopyridines. US0209550; 2009
120. Neurosearch A/S. 4-Phenyl-piperazin-1-yl-alkyl-benzoimidazol-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO092720; 2009
121. Neurosearch A/S. Piperazinyl-alkylbenzoimidazol-2-one derivatives and their use as monoamine neurotransmitter reuptake inhibitors. WO032903; 2011
122. CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. Benzothiophene alkanol piperazine derivatives and their use as antidepressant. WO000198; 2010
123. CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. The 1-butyl-2-hydroxyyaralkyl piperazine derivatives and their uses as antidepression medicine therefore. WO040315; 2010
124. CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. Optical isomers of aralkyl piperazine derivative, preparation methods and uses thereof. WO054185; 2011
125. CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. Preparation method of optical isomers of 1-butyl-2-hydroxy-aralkyl alcohol piperazine derivative. WO054183; 2011
126. Brogden RN, Heel RC, Speight TM, Avery GS. Nomifensine: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs 1979;18:1-24
127. AMR Technology, Inc & Bristol-Myers Squibb Co. Aryl-and heteroarylsubstituted tetrahydroisoquinolines and use therefore to block reuptake of norepinephrine, dopamine and serotonin. WO020049; 2006
128. Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof. US0292242; 2010
129. Albany Molecular Research, Inc. 7-([1,2,4] triazolo[1,5-a]pyridine-6-yl)- 4-(3, 4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof. WO132442; 2010
130. Bristol-Myers Squib Co. The crystalline forms of (S)-7-([1,2,4] triazolo[1,5a] pyridine-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro isoquinoline and use thereof. WO132487; 2010
131. Panacea Biotec Ltd. Novel monoamine re-uptake inhibitor. WO118765;2009
132. AMR Technology, Inc & Bristol-Myers Squibb Co. Aryl-and heteroarylsubstituted tetrahydrobenzazepines and use therefore to block reuptake of norepinephrine, dopamine and serotonin. WO011820; 2007
133. AMR Technology, Inc & Bristol-Myers Squibb Co. Aryl-and heteroarylsubstituted tetrahydrobenzo-1,4-diazepines. WO141081; 2008
134. AMR Technology, Inc & Bristol-Myers Squibb Co. Aryloxy-and heteroaryloxysubstituted tetrahydrobenzazepines and use therefore to block reuptake of norepinephrine, dopamine and serotonin. WO141082; 2008
135. OTSUKA Pharmaceutical Co., Ltd. In 1-position durch einen ring substitute benzo[1, 4] diazepine zur verwendungs als antidepressiva. JP20111111419; WO145357; 2009
136. Glaxosmithkine istrazivacki centar Zagreb D.O.O. Tetracyclic monoamine reuptake inhibitors for treatment of CNS diseases and disorders. WO109190; 2006
137. Tanaka S. 6-amino alkylene 6,7-dihydro-5H-dibenzo[b.g][1,5]thiazocines. US3803143; 1970
138. Lundbeck A.S. 2-(1H-indolylsulfanyl)-aryl amine derivatives for use in their treatment of affective disorders, pain, ADHD and stress urinary incontinence. WO007843; 2006
139. Universite De Rouen. Neuroactive plant extract from hypericum polyanthemum. WO092162; 2010
140. Meyer JH, Wilson AA, Ginovart N, et al. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [11C] DASB PET imaging study. J Psychiatry 2001;158:1843-9
141. Meyer JH, Wilson AA, Sagrati S, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 2004;161:826-35
142. Suhara T, Takano A, Sudo Y, et al. High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry 2003;60:386-91
143. Takano A, Suzuki K, Kosaka J, et al. A dose-finding study of duloxetine based on serotonin transporter occupancy. Psychopharmacology (Berl) 2006;185:395-9